Chemotherapy of prostate cancer: present and future.
The role of chemotherapy in prostate cancer continues to evolve. In men with symptomatic androgen-independent prostate cancer, significant reduction in pain and analgesic requirements are achievable with mitoxantrone and glucocorticoid combinations compared with glucocorticoids alone. However, survival rates are not improved. Taxane-based combinations with estramustine phosphate or other new agents show promise. Prostate-specific antigen response rates with these combinations appear to be 1.5 to 2 times more frequent than with mitoxantrone-based combinations. Randomized trials of taxane versus mitoxantrone-based therapies are underway. New agents and applications of current agents in adjuvant settings should be explored if survival in men with prostate cancer is to be improved.
Trump
Donald
D
Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA. donald.trump@roswellpark.org
Lau
Yiu-Keung
YK
D000970:Antineoplastic Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001952:Bridged-Ring Compounds / Q000627:therapeutic use; D002117:Calcitriol / Q000627:therapeutic use; D002120:Calcium Channel Agonists / Q000627:therapeutic use; D004358:Drug Therapy / Q000639:trends*; D004961:Estramustine / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D043823:Taxoids
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D001952:Bridged-Ring Compounds; D002120:Calcium Channel Agonists; D043823:Taxoids; C080625:taxane; D004961:Estramustine; D008942:Mitoxantrone; D002117:Calcitriol